# US 2012/0269815 A1 · Neurotrophins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269815 A1
- Document ID: US20120269815A1
- Status: Published application
- Kind: A1
- Application number: 13/141,526
- Filed: 2009-12-23
- Published: 2012-10-25
- Earliest claimed: 2008-12-23
- Assignees: Regents of the University of Minnesota
- Inventors: Phu V. Tran
- Web page: https://patentgrep.com/patent/US20120269815A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/12: Antihypertensives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/475: Growth factors; Growth regulators
- C07K 16/22: against growth factors {; against growth regulators}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/475: Assays involving growth factors
- G01N 2800/2821: Alzheimer
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N 2800/321: Arterial hypertension
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A neurotrophin polypeptide, and a biologically active fragment thereof, are described. Also, methods are disclosed that include providing a composition comprising the neurotrophin polypeptide to a subject, wherein the composition is effective to ameliorate at least one symptom or clinical sign of a condition treatable with a neurotrophin when the composition is administered to a subject in need of treatment for a condition treatable with a neurotrophin.

## Claims

### Claim 1

An isolated TUF1 polypeptide comprising an amino acid sequence having at least 83% sequence similarity to the amino acid sequence depicted in SEQ ID NO:1.

### Claim 2 (depends on 1)

The isolated TUF1 polypeptide of claim 1 wherein the TUF1 polypeptide comprises an amino acid sequence having at least 83% sequence identity to the amino acid sequence depicted in SEQ ID NO:1.

### Claim at position 3

3-35. (canceled)

### Claim 36 (depends on 1)

A composition comprising the isolated polypeptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 37

An isolated TUF1 polypeptide comprising an amino acid sequence having at least 83% sequence similarity to the amino acid sequence depicted in SEQ ID NO:2.

### Claim 38 (depends on 37)

The isolated TUF 1 polypeptide of claim 37 wherein the TUF1 polypeptide comprises an amino acid sequence having at least 83% sequence identity to the amino acid sequence depicted in SEQ ID NO:2.

### Claim 39 (depends on 37)

A composition comprising the isolated polypeptide of claim 37 and a pharmaceutically acceptable carrier.

### Claim 40

An isolated polynucleotide that encodes a TUF1 polypeptide, wherein the TUF1 polypeptide comprises an amino acid sequence having at least 83% sequence similarity to the amino acid sequence depicted in SEQ ID NO:1.

### Claim 41 (depends on 40)

The isolated polynucleotide of claim 40 wherein the TUF1 polypeptide comprises an amino acid sequence having at least 83% sequence identity to the amino acid sequence depicted in SEQ ID NO:1.

### Claim 42 (depends on 40)

A composition comprising the isolated polynucleotide of claim 40 and a pharmaceutically acceptable carrier.

### Claim 43

An isolated polynucleotide that encodes a TUF1 polypeptide, wherein the TUF1 polypeptide comprises an amino acid sequence having at least 83% sequence similarity to the amino acid sequence depicted in SEQ ID NO:2.

### Claim 44 (depends on 43)

The isolated polynucleotide of claim 43 wherein the TUF1 polypeptide comprises an amino acid sequence having at least 83% sequence identity to the amino acid sequence depicted in SEQ ID NO:2.

### Claim 45 (depends on 43)

A composition comprising the isolated polynucleotide of claim 43 and a pharmaceutically acceptable carrier.

### Claim 46

An antibody composition that specifically binds to at least a portion of a TUF1 polypeptide, wherein the antibody specifically binds to at least a portion of the amino acid sequence depicted in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.

### Claim 47 (depends on 46)

The antibody composition of claim 46 wherein the antibody specifically binds to at least a portion of amino acids 6-20 of SEQ ID NO:3.

### Claim 48 (depends on 46)

The antibody composition of claim 46 comprising polyclonal antibody.

### Claim 49 (depends on 46)

The antibody composition of claim 46 comprising a monoclonal antibody.

### Claim 50 (depends on 46)

The antibody composition of claim 46 comprising a pharmaceutically acceptable carrier.

### Claim 51

A method comprising:
providing a composition comprising a TUF1 polypeptide, wherein the composition is effective to ameliorate at least one symptom or clinical sign of a condition treatable with a neurotrophin when the composition is administered to a subject in need of treatment for a condition treatable with a neurotrophin.

### Claim 52 (depends on 51)

The method of claim 51 wherein the condition comprises brain injury.

### Claim 53 (depends on 51)

The method of claim 51 wherein the condition comprises a fear disorder or anxiety disorder.

### Claim 54 (depends on 51)

The method of claim 51 wherein the condition comprises male fertility.

### Claim 55 (depends on 51)

The method of claim 51 wherein the composition comprises a TUF1 polypeptide comprising an amino acid sequence having at least 83% sequence similarity to the amino acid sequence depicted in SEQ ID NO:1.

### Claim 56 (depends on 51)

The method of claim 51 wherein the composition comprises a TUF1 polypeptide comprising an amino acid sequence having at least 83% sequence similarity to the amino acid sequence depicted in SEQ ID NO:2.

### Claim 57

A method comprising:
detecting expression of TUF1 in a tissue of a subject, wherein detecting TUF1 expression in the tissue indicates that the subject is at least at risk for developing a condition.

### Claim 58 (depends on 57)

The method of claim 57 wherein the condition comprises hypertension.

### Claim 59 (depends on 57)

The method of claim 57 wherein the condition comprises Huntington's Disease.

### Claim 60 (depends on 57)

The method of claim 57 wherein the condition comprises Alzheimer's Disease.

### Claim 61 (depends on 57)

The method of claim 57 wherein the condition comprises Parkinson's Disease.

### Claim 62

A method comprising:
providing a composition comprising a TUF1 inhibitor, wherein administering an effective amount of the composition to a subject inhibits at least one activity of TUF1 in the subject.

### Claim 63 (depends on 62)

The method of claim 62 wherein the composition comprises an isolated polynucleotide that encodes a TUF1 polypeptide, wherein the TUF1 polypeptide comprises an amino acid sequence having at least 83% sequence similarity to the amino acid sequence depicted in SEQ ID NO:1.

### Claim 64 (depends on 63)

The method of claim 63 wherein the isolated polynucleotide comprises a siRNA that targets at least a portion of a polynucleotide that encodes TUF1 or an RNAi that targets at least a portion of a polynucleotide that encodes TUF1.

### Claim 65 (depends on 62)

The method of claim 62 wherein the composition comprises an isolated polynucleotide that encodes a TUF1 polypeptide, wherein the TUF1 polypeptide comprises an amino acid sequence having at least 83% sequence similarity to the amino acid sequence depicted in SEQ ID NO:2.

### Claim 66 (depends on 65)

The method of claim 65 wherein the isolated polynucleotide comprises a siRNA that targets at least a portion of a polynucleotide that encodes TUF1 or an RNAi that targets at least a portion of a polynucleotide that encodes TUF1.

### Claim 67 (depends on 62)

The method of claim 62 wherein the composition comprises an antibody composition.

### Claim 68 (depends on 67)

The method of claim 67 wherein the antibody composition comprises antibody that specifically binds to at least a portion of the amino acid sequence depicted in SEQ ID NO:1, at least a portion of the amino acid sequence depicted in SEQ ID NO:2, at least a portion of the amino acid sequence depicted in SEQ ID NO:3, or at least a portion of the amino acid sequence depicted in SEQ ID NO:4.

### Claim 69 (depends on 68)

The method of claim 68 wherein the antibody specifically binds to at least a portion of amino acids 6-20 of SEQ ID NO:3.

### Claim 70 (depends on 67)

The method of claim 67 wherein the antibody composition comprises polyclonal antibody.

### Claim 71 (depends on 67)

The method of claim 67 wherein the antibody composition comprises a monoclonal antibody.

### Claim 72 (depends on 62)

The method of claim 62 wherein the condition comprises hypertension.

### Claim 73 (depends on 62)

The method of claim 62 wherein the condition comprises obesity.
